Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

IGC Pharma (IGC) Shares Outstanding (2016 - 2025)

IGC Pharma has reported Shares Outstanding over the past 15 years, most recently at $92.0 million for Q3 2025.

  • Quarterly Shares Outstanding rose 19.99% to $92.0 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $92.0 million through Sep 2025, up 19.99% year-over-year, with the annual reading at $80.9 million for FY2025, 21.27% up from the prior year.
  • Shares Outstanding was $92.0 million for Q3 2025 at IGC Pharma, up from $84.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $92.0 million in Q3 2025 and troughed at $47.8 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $53.1 million (2022), against an average of $62.9 million.
  • Year-over-year, Shares Outstanding increased 2.38% in 2023 and then soared 42.5% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $51.1 million in 2021, then rose by 3.96% to $53.1 million in 2022, then rose by 20.08% to $63.7 million in 2023, then grew by 22.7% to $78.2 million in 2024, then rose by 17.59% to $92.0 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Shares Outstanding are $92.0 million (Q3 2025), $84.1 million (Q2 2025), and $80.9 million (Q1 2025).